CR20120594A - Compuestos heteroarilo nitrogenados - Google Patents

Compuestos heteroarilo nitrogenados

Info

Publication number
CR20120594A
CR20120594A CR20120594A CR20120594A CR20120594A CR 20120594 A CR20120594 A CR 20120594A CR 20120594 A CR20120594 A CR 20120594A CR 20120594 A CR20120594 A CR 20120594A CR 20120594 A CR20120594 A CR 20120594A
Authority
CR
Costa Rica
Prior art keywords
compounds
heteroarilo
nitrogen
drugs
salts
Prior art date
Application number
CR20120594A
Other languages
English (en)
Inventor
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Felix Gruber
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Sarmiento Rosa Maria Rodriguez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20120594A publication Critical patent/CR20120594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos heteroarilo nitrogenados de fórmula (I), en la que A1,A2, , R1, R2, R3, R4, R5 y R6 son tal como se define en la descripción y en las reivindicaciones, así como sales y ésteres fisiológicamente aceptables de los mismos. Dichos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos.
CR20120594A 2010-06-09 2012-11-26 Compuestos heteroarilo nitrogenados CR20120594A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10165427 2010-06-09

Publications (1)

Publication Number Publication Date
CR20120594A true CR20120594A (es) 2013-01-03

Family

ID=44483879

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120594A CR20120594A (es) 2010-06-09 2012-11-26 Compuestos heteroarilo nitrogenados

Country Status (24)

Country Link
US (1) US8703768B2 (es)
EP (1) EP2580207B1 (es)
JP (1) JP5940523B2 (es)
KR (1) KR101757959B1 (es)
CN (1) CN102947292B (es)
AR (1) AR081649A1 (es)
BR (1) BR112012031343A2 (es)
CA (1) CA2799022A1 (es)
CL (1) CL2012003421A1 (es)
CO (1) CO6620065A2 (es)
CR (1) CR20120594A (es)
EA (1) EA022075B1 (es)
EC (1) ECSP12012330A (es)
IL (1) IL223069A0 (es)
MA (1) MA34340B1 (es)
MX (1) MX2012013907A (es)
NZ (1) NZ603230A (es)
PE (1) PE20130279A1 (es)
PH (1) PH12012502335A1 (es)
SG (1) SG185655A1 (es)
TW (1) TW201202221A (es)
UA (1) UA108105C2 (es)
WO (1) WO2011154327A1 (es)
ZA (1) ZA201209119B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044054A1 (en) * 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
EA201290957A1 (ru) 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
CA2845191A1 (en) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
HUE043059T2 (hu) 2013-02-27 2019-07-29 Mochida Pharm Co Ltd Új pirazolszármazék
JP6212628B2 (ja) * 2013-04-29 2017-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２−フェニル又は２−ヘタリールイミダゾール［１，２−ａ］ピリジン誘導体
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EA038960B1 (ru) * 2015-01-30 2021-11-15 Басф Се Гербицидные фенилпиримидины
ES2841452T3 (es) * 2015-02-06 2021-07-08 Merck Patent Gmbh Macrociclos de piridazinona como inhibidores de IRAK y sus usos
CN104610189A (zh) * 2015-02-10 2015-05-13 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途
CN104974075A (zh) * 2015-08-07 2015-10-14 新秀化学（烟台）有限公司 一种n, n-二(2,2,6,6-四甲基-4-哌啶基) -1,3-苯二甲酰胺的制备方法
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3490985B1 (en) 2016-07-26 2020-08-05 Basf Se Herbicidal pyrimidine compounds
WO2018019767A1 (en) 2016-07-27 2018-02-01 Basf Se Herbicidal pyridine compounds
BR112018077223A2 (pt) 2016-07-27 2019-04-09 Basf Se compostos de pirimidina, uso de compostos de pirimidina, composições herbicidas, método para controlar vegetação indesejada e uso das composições herbicidas
CA3030217A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyrimidine compounds
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
US12024510B2 (en) * 2017-12-20 2024-07-02 Pi Industries Ltd. Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same
US11389987B2 (en) 2018-06-29 2022-07-19 Synthes Gmbh Hybrid saw blade
CA3112955A1 (en) 2018-09-19 2020-03-26 Bayer Aktiengesellschaft Herbicidally active substituted phenylpyrimidine hydrazides
KR102860523B1 (ko) * 2018-11-02 2025-09-16 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드
EP4052760B1 (en) 2019-10-31 2024-03-13 FUJIFILM Corporation Pyrazine derivative or salt thereof, and use of same
EP4190402B1 (en) 2020-07-30 2025-08-27 FUJIFILM Corporation Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof
EP4244210A4 (en) 2020-11-13 2024-10-30 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
US12617772B2 (en) 2021-04-05 2026-05-05 Inipharm, Inc. Hydroxypyridine HSD17B13 inhibitors and uses thereof
WO2022216627A1 (en) * 2021-04-05 2022-10-13 Inipharm, Inc. Thiazole/isothiazole hsd17b13 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2007524682A (ja) 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
US7414060B2 (en) * 2005-03-04 2008-08-19 Hoffmann-La Roche Inc. Pyridine-2-carboxyamide derivatives
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
US20090105124A1 (en) 2007-08-23 2009-04-23 Kalypsys, Inc. Heterocyclic modulators of tgr5
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives

Also Published As

Publication number Publication date
MX2012013907A (es) 2012-12-17
UA108105C2 (ru) 2015-03-25
NZ603230A (en) 2013-09-27
EP2580207B1 (en) 2017-09-27
EA022075B1 (ru) 2015-10-30
CL2012003421A1 (es) 2013-07-26
PE20130279A1 (es) 2013-03-08
ZA201209119B (en) 2015-05-27
CA2799022A1 (en) 2011-12-15
AR081649A1 (es) 2012-10-10
CN102947292B (zh) 2015-08-19
ECSP12012330A (es) 2012-12-28
CN102947292A (zh) 2013-02-27
BR112012031343A2 (pt) 2016-11-01
KR20130112858A (ko) 2013-10-14
IL223069A0 (en) 2013-02-03
SG185655A1 (en) 2012-12-28
WO2011154327A1 (en) 2011-12-15
MA34340B1 (fr) 2013-06-01
JP2013528193A (ja) 2013-07-08
CO6620065A2 (es) 2013-02-15
US8703768B2 (en) 2014-04-22
KR101757959B1 (ko) 2017-07-14
US20110306589A1 (en) 2011-12-15
EA201291282A1 (ru) 2013-06-28
HK1178900A1 (en) 2013-09-19
JP5940523B2 (ja) 2016-06-29
TW201202221A (en) 2012-01-16
EP2580207A1 (en) 2013-04-17
PH12012502335A1 (en) 2013-02-11

Similar Documents

Publication Publication Date Title
ECSP12012330A (es) Compuestos heteroarilo nitrogenados
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
CO6541606A2 (es) Espiroindolinona- pirrolidinas
CR20150250A (es) Nuevos derivados de piridina
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
CR20130239A (es) Compuestos de triazolopiridina
ECSP13013074A (es) Nuevos derivados de piridina
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
MX336381B (es) Boronatos como inhibidores de arginasa.
CO6511272A2 (es) Compustos de pirazol como antahonistas de crth2
NZ704147A (en) Partially saturated nitrogen-containing heterocyclic compound
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
CR20150204A (es) Nuevos derivados de piridina
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2014014468A (es) Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10).
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
CO7170173A2 (es) Derivados de carbamato/urea
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
MX350009B (es) Derivados de 2-metoxi-piridin-4-ilo.
CR20150073A (es) Nuevos derivados de piridina
BR112015010469A2 (pt) derivados de imidazopiridina
HN2012000485A (es) Nuevos derivados dihidro-oxazolobenzonzodiazepinonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
GT201300067A (es) Nuevos derivados dihidrobenzoxatiazepinas. su procedimiento de preparacion y las composiciones farmaceuticas que los
MX351093B (es) Nuevos derivados de azetidina.